Taysha Gene Therapies (NASDAQ:TSHA) Receives “Overweight” Rating from Cantor Fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $7.00 price objective on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 208.37% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Chardan Capital boosted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Finally, Piper Sandler started coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price objective for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus target price of $6.88.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $2.27 on Thursday. The stock has a market capitalization of $424.54 million, a price-to-earnings ratio of -3.39 and a beta of 0.29. Taysha Gene Therapies has a twelve month low of $0.50 and a twelve month high of $3.89. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. The stock has a 50-day moving average of $2.56 and a 200 day moving average of $2.10.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently made changes to their positions in TSHA. FMR LLC grew its position in shares of Taysha Gene Therapies by 2,035.0% in the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Taysha Gene Therapies in the third quarter valued at approximately $58,373,000. RTW Investments LP acquired a new position in Taysha Gene Therapies in the third quarter valued at approximately $53,382,000. Acuta Capital Partners LLC acquired a new position in Taysha Gene Therapies in the third quarter valued at approximately $12,096,000. Finally, Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 235.2% in the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock valued at $16,836,000 after acquiring an additional 3,738,616 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.